Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Children who experience multiple cases of dengue virus develop an army of dengue-fighting T cells, according to a new study ...

Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following ...

Researchers identify mitochondrial transfer between cancer and immune cells as a crucial mechanism for immune evasion. The ...

Swarm Oncology Ltd., a biotechnology company, has partnered with Cellex Cell Professionals GmbH, a contract development and ...

Alcohol on the other hand makes it easy to fall asleep but as the effects wear off, you’re likely to experience frequent ...

A NZ trial using immunotherapy to beat a form of blood cancer is expanding after promising results – and it’s hoped the ‘gold standard’ treatment will soon be widely available. It took just one minute ...

Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.

Celularity Inc. (Nasdaq: CELU) ("Celularity” or the "Company”), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with ...

In this video, Tanya Dorff, MD discusses the greatest unmet needs in the treatment of castration-resistant prostate cancer.